Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Ritchlin, Christopher T. [1 ]
Mease, Philip J. [2 ,3 ]
Boehncke, Wolf-Henning [4 ]
Tesser, John [5 ]
Chakravarty, Soumya D. [6 ,7 ]
Rampakakis, Emmanouil [8 ,9 ]
Shawi, May [10 ]
Merola, Joseph F. [11 ]
McInnes, Iain B. [12 ]
Deodhar, Atul [13 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA
[3] Univ Washington, Seattle, WA USA
[4] Univ Geneva, Univ Hosp Geneva, Div Dermatol, Geneva, Switzerland
[5] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA
[6] Janssen Sci Affairs LLC, Horsham, PA USA
[7] Drexel Univ, Coll Med, Philadelphia, PA USA
[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada
[9] JSS Med Res Inc, Montreal, PQ, Canada
[10] Johnson & Johnson, Janssen Pharmaceut Co, Immunol Global Med Affairs, Horsham, PA USA
[11] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol & Immunol, Boston, MA USA
[12] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[13] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42148
引用
收藏
页码：AB225 / AB225
页数：1
相关论文
共 50 条
  • [41] Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
    Deodhar, Atul
    Mease, Philip
    Boehncke, Wolf-Henning
    Tesser, John
    Schiopu, Elena
    Chakravarty, Soumya
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Agarwal, Prasheen
    Merola, Joseph
    McInnes, Iain
    Ritchlin, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study
    Tanaka, Yoshiya
    Kawai, Shinichi
    Takeuchi, Tsutomu
    Yamamoto, Kazuhiko
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2013, 23 (06) : 1045 - 1052
  • [43] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
    Gottlieb, Alice
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Hsia, Elizabeth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
  • [44] Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
    Nangaku, Masanomi
    Takama, Hirotaka
    Ichikawa, Tomohiro
    Mukai, Kazuya
    Kojima, Masahiro
    Suzuki, Yusuke
    Watada, Hirotaka
    Wada, Takashi
    Ueki, Kohjiro
    Narita, Ichiei
    Kashihara, Naoki
    Kadowaki, Takashi
    Hase, Hiroki
    Akizawa, Tadao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (05) : 1204 - 1216
  • [45] A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease
    Howard, Joanna
    Kuo, Kevin H. M.
    Oluyadi, Abdulafeez
    Shao, Hui
    Morris, Susan
    Zaidi, Ahmar U.
    Van Beers, Eduard J.
    Thien, Swee Lay
    BLOOD, 2021, 138
  • [46] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Gladman, D. D.
    Mease, P. J.
    Bird, P.
    Soriano, E.
    Chakravarty, S. D.
    Shawi, M.
    Xu, S.
    Quinn, S.
    Gong, C.
    Leibowitz, E.
    Tam, L. S.
    Helliwell, P.
    Kavanaugh, A.
    Deodhar, A.
    Ostergaard, M.
    Baraliakos, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
  • [47] GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDIES
    Kavanaugh, A.
    Soriano, E.
    Dutz, J.
    Selmi, C.
    Yu, J.
    Rampakakis, E.
    Shawi, M.
    Bravo Perdomo, A. M.
    Lavie, F.
    Coates, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1770 - 1771
  • [48] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
    Christopher T. Ritchlin
    Laura C. Coates
    Philip J. Mease
    Désirée van der Heijde
    Jiao Song
    Yusang Jiang
    May Shawi
    Alexa P. Kollmeier
    Proton Rahman
    Trials, 24
  • [49] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
    Ritchlin, Christopher T.
    Coates, Laura C.
    Mease, Philip J.
    van der Heijde, Desiree
    Song, Jiao
    Jiang, Yusang
    Shawi, May
    Kollmeier, Alexa P.
    Rahman, Proton
    TRIALS, 2023, 24 (01)
  • [50] Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
    Kornstein, Susan
    Chang, Cheng-Tao
    Gommoll, Carl P.
    Edwards, John
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (04) : 217 - 223
12345